Drug Trial Radar · NCT06236308
TTAX03 for the Treatment of Lumbosacral Facet Joint Pain
Last checked: Nov 19, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jul 15, 2024
Primary completion
Jan 31, 2025
Study completion Mar 4, 2025
Sponsor
- Lead sponsor
- BioTissue Holdings, IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 35 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a pilot study examining the safety and efficacy of a single intra-articular (IA) injection of TTAX03 per joint to relieve severe spinal facet joint (FJ) pain and improve function in subjects with facet joint pain (FJP) in the lumbosacral region. The design is randomized, double blinded, placebo controlled and dose-group sequential.
Conditions
- Facet Joint Pain
Interventions
TTAX03 10mgBiological
TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic techniques followed by terminal sterilization by gamma-irradiation in compliance with Current Good Tissue Practices (CGTP) and Current Good Manufacturing Practices (CGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells.
TTAX03 25mgBiological
TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic techniques followed by terminal sterilization by gamma-irradiation in compliance with Current Good Tissue Practices (CGTP) and Current Good Manufacturing Practices (CGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells.
Placebo Comparator: Control SalineBiological
2 mL Sterile, preservative free 0.9% NaCl
Primary outcomes
What the sponsor says the trial is designed to measure.
- Physical, functional and physiological responses to the intervention, as well as unanticipated eventsTime frame: 12-weeks post baseline
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.